Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Thymus polypeptide is a mixture of peptides derived from the thymus gland, and it has been studied for its potential to modulate the immune system, particularly in the context of chemotherapy-induced immunosuppression. The use of thymic peptides, such as thymosin alpha-1 and thymopentin, has been investigated in several clinical trials primarily in China and Europe. These studies suggest that thymus polypeptides may help restore immune function, reduce infection rates, and improve tolerance to chemotherapy in cancer patients. A 2013 meta-analysis (Curr Med Res Opin) of randomized controlled trials indicated that thymosin alpha-1 can decrease the incidence of chemotherapy-induced neutropenia and infections, and may improve overall quality of life, though the studies were generally of moderate quality and sometimes at risk of bias.

Despite these promising findings, the evidence is not unequivocal. Most studies are small-scale, and there is a lack of large, high-quality, multicenter randomized trials published in major international journals. Regulatory agencies like the FDA and EMA have not approved thymus polypeptides specifically for managing chemotherapy side effects. As a result, while there is moderate scientific support for the use of thymus polypeptides to reduce certain side effects of chemotherapy, particularly immunosuppression and infection, further rigorous research is needed to confirm efficacy and safety.

More about Thymus polypeptide
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Thymus polypeptide

Products containing Thymus polypeptide